Five things for pharma marketers to know: Friday, October 23, 2015
1. Amgen is reportedly asking patients who apply for co-pay assistance for Repatha, the drugmaker's new PCSK9 inhibitor, for access to their personal health information for 10 years, according to MedPage Today. The information would also be given, with few restrictions, to unspecific third parties, the site reported. Amgen had not responded for comment.
2. Valeant Pharmaceuticals remains under scrutiny as investors continue to question the company's close ties to pharmacies that sell its drugs, reported Bloomberg Business. Even PhRMA, the industry trade group, has started to distance Valeant's M&A-focused business model from that of traditional pharma companies that conduct their own R&D. The drugmakers is planning to hold an investor call on Monday.
3. The FDA approved Johnson & Johnson's Yondelis (trabectedin), a chemotherapy used to treat metastatic liposarcoma and leiomyosarcoma. The agency estimates that there were 12,000 diagnoses of specific soft-tissue sarcomas in 2014. The drug received Priority Review status in February.
4. The controversy over Turing Pharmaceuticals' price hike for Daraprim has taken another turn. Imprimis Pharmaceuticals, a San Diego–based compounding pharmacy, said it will sell customized versions of the toxoplasmosis treatment that cost less than $1 a pill, according to USA Today. Daraprim used to cost $13.50 per pill before Turing raised the price to $750 a pill. Turing later said it would lower the price but did not disclose the change.
5. European regulators recommended that the European Medicines Agency approve Imlygic, Amgen's experimental melanoma treatment, according to Reuters. The drug, talimogene laherparepvec, or "T-Vec," uses a modified herpes simplex virus to infect and kill cancer cells. The FDA is expected to make a decision Tuesday on whether to approve the drug.